{"title":"更正 \"新型药物时代诱导治疗的临床结果以及高危细胞遗传学异常（HRA）数量对新诊断多发性骨髓瘤（NDMM）患者预后的影响：一项多中心研究的启示》。","authors":"","doi":"10.1002/cam4.70406","DOIUrl":null,"url":null,"abstract":"<p>This corrects the article “Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study” PMID: 39422477 PMCID: PMC11487677 DOI: 10.1002/cam4.70270</p><p>The correct affiliations for Xiaojin Li are as follows:</p><p>2. Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, Yunnan, China</p><p>3. The Affiliated Hospital of Yunnan University, Kunming, Yunnan, China</p><p>The correct title of Table 4 is “Baseline characteristics of patients without HRA, those with 1 HRA and those with ≥ 2 HRA”</p><p>We apologize for these errors.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 21","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551253/pdf/","citationCount":"0","resultStr":"{\"title\":\"Correction to “Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study”\",\"authors\":\"\",\"doi\":\"10.1002/cam4.70406\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This corrects the article “Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study” PMID: 39422477 PMCID: PMC11487677 DOI: 10.1002/cam4.70270</p><p>The correct affiliations for Xiaojin Li are as follows:</p><p>2. Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, Yunnan, China</p><p>3. The Affiliated Hospital of Yunnan University, Kunming, Yunnan, China</p><p>The correct title of Table 4 is “Baseline characteristics of patients without HRA, those with 1 HRA and those with ≥ 2 HRA”</p><p>We apologize for these errors.</p>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"13 21\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551253/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70406\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70406","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
文章 "新型药物时代诱导治疗的临床结果及高危细胞遗传学异常（HRA）数量对新诊断多发性骨髓瘤（NDMM）患者预后的影响：一项多中心研究的启示" PMID: 39422477 PMCID: PMC11487677 DOI: 10.1002/cam4.70270 李晓津的正确单位如下：2. 昆明理工大学环境科学与工程学院，中国云南昆明3.表 4 的正确标题是 "无 HRA、1 例 HRA 和≥2 例 HRA 患者的基线特征"，我们对这些错误表示歉意。
Correction to “Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study”
This corrects the article “Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study” PMID: 39422477 PMCID: PMC11487677 DOI: 10.1002/cam4.70270
The correct affiliations for Xiaojin Li are as follows:
2. Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, Yunnan, China
3. The Affiliated Hospital of Yunnan University, Kunming, Yunnan, China
The correct title of Table 4 is “Baseline characteristics of patients without HRA, those with 1 HRA and those with ≥ 2 HRA”
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
